AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic
AbCellera (Nasdaq: ABCL) has commenced the second phase of its global headquarters expansion in Vancouver, Canada, with a new 380,000-square-foot tech campus. This facility will enhance lab and office capabilities to support the company's objectives in antibody-based medicine development. The expansion aims to accommodate its growing workforce of over 450 employees and advance its integrated solutions for biopharma partners. The completion of this facility is planned for 2025, following the first phase scheduled for late 2023.
- Launch of a 380,000-square-foot tech campus will enhance laboratory and office capabilities.
- Expansion supports AbCellera's growth, facilitating more efficient drug development processes.
- The project will create new job opportunities, attracting top-tier talent in the industry.
- None.
“With our current capabilities, we are able to find optimal clinical antibody candidates with greater precision and speed, ultimately helping our partners bring medicines to patients sooner,” said
AbCellera empowers its emerging biopharma partners to advance discovery programs without having to build the underlying capabilities, teams, and infrastructure. For its large biopharma partners, AbCellera’s integrated technologies allow intractable programs to be unlocked seamlessly within a single platform.
“We are recruiting for positions across the organization and continue to attract top-tier talent who are excited to do meaningful work that helps advance innovative new medicines for patients,” said
AbCellera broke ground on the first phase of its global headquarters in the heart of
About
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.
AbCellera Forward-looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005283/en/
Media:
Business Development:
Investor Relations:
Source:
FAQ
What is the significance of AbCellera's new headquarters expansion?
When is the completion date for AbCellera's new facility?
How many employees does AbCellera currently have?